Amanote Research
Register
Sign In
Retraction Note To: Suppression of the xCT–CD44v Antiporter System Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin
Breast Cancer Research and Treatment
- Netherlands
doi 10.1007/s10549-015-3399-y
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
May 1, 2015
Authors
Feng Wang
Yong Yang
Publisher
Springer Science and Business Media LLC
Related search
Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin
Oncotarget
Oncology
PARP Inhibition Sensitizes P53-Deficient Breast Cancer Cells to Doxorubicin-Induced Apoptosis
Biochemical Journal
Biochemistry
Cell Biology
Molecular Biology
Fighting Breast Cancer Stem Cells Through the Immune-Targeting of the xCT Cystine–glutamate Antiporter
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells
British Journal of Cancer
Cancer Research
Oncology
CREB3L1 as a Potential Biomarker Predicting Response of Triple Negative Breast Cancer to Doxorubicin-Based Chemotherapy
BMC Cancer
Cancer Research
Oncology
Genetics
FZD7 in Triple Negative Breast Cancer Cells
Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin
Curcumin Restores Sensitivity to Retinoic Acid in Triple Negative Breast Cancer Cells
BMC Cancer
Cancer Research
Oncology
Genetics
Triple-Negative Breast Cancer